Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Immunologic Research
Published in: Immunologic Research 1-3/2010

01-12-2010

Thinking about HIV: the intersection of virus, neuroinflammation and cognitive dysfunction

Authors: K. Grovit-Ferbas, M. E. Harris-White

Published in: Immunologic Research | Issue 1-3/2010

Login to get access

Abstract

It is estimated that half of HIV-infected adults and children will present at one time during their disease course with a neurologic disorder. The neurologic sequelae of HIV infection arise as a direct result of viral replication as well as from the subsequent neuroinflammatory processes. HIV enters the CNS early in infection and resides primarily in long-lived perivascular macrophages and microglia. CNS immunosurveillance is an integral part of normal brain function. Circulating lymphocytes play a vital role in support of brain plasticity under normal and traumatic circumstances. Malfunctions of this immunologic niche can impair brain homeostasis, resulting in neural impairment. Combination therapies that lower CNS viral load and improve immune homeostasis and neuroprotection will be required to address the neuropathogenesis of HIV infection.
Literature
1.
WHO/UNAIDS. Report on the global AIDS epidemic; 2009.
2.
Kaul M, Zheng J, Okamoto S, Gendelman HE, Lipton SA. HIV-1 infection and AIDS: consequences for the central nervous system. Cell Death Differ. 2005;12(Suppl 1):878–92. 15832177.PubMedCrossRef
3.
Williams KC, Corey S, Westmoreland SV, Pauley D, Knight H, deBakker C, Alvarez X, Lackner AA. Perivascular macrophages are the primary cell type productively infected by simian immunodeficiency virus in the brains of macaques: implications for the neuropathogenesis of AIDS. J Exp Med. 2001;193(8):905–15.PubMedCrossRef
4.
Bissel SJ, Wiley CA. Human immunodeficiency virus infection of the brain: pitfalls in evaluating infected/affected cell populations. Brain Pathol. 2004;14(1):97–108.PubMedCrossRef
5.
Fischer-Smith T, Bell C, Croul S, Lewis M, Rappaport J. Monocyte/macrophage trafficking in acquired immunodeficiency syndrome encephalitis: lessons from human and nonhuman primate studies. J Neurovirol. 2008;14(4):318–26.PubMedCrossRef
6.
Cosenza MA, Zhao ML, Si Q, Lee SC. Human brain parenchymal microglia express CD14 and CD45 and are productively infected by HIV-1 in HIV-1 encephalitis. Brain Pathol. 2002;12(4):442–55.PubMedCrossRef
7.
Yi Y, Lee C, Liu QH, Freedman BD, Collman RG. Chemokine receptor utilization and macrophage signaling by human immunodeficiency virus type 1 gp120: implications for neuropathogenesis. J Neurovirol. 2004;10(Suppl 1):91–6. 14982745.PubMed
8.
Agrawal L, Louboutin JP, Marusich E, Reyes BA, Van Bockstaele EJ, Strayer DS. Dopaminergic neurotoxicity of HIV-1 gp120: reactive oxygen species as signaling intermediates. Brain Res. 2010;1306:116–30. Epub@2009 Oct 6.:116-30.PubMedCrossRef
9.
An SF, Groves M, Giometto B, Beckett AA, Scaravilli F. Detection and localisation of HIV-1 DNA and RNA in fixed adult AIDS brain by polymerase chain reaction/in situ hybridisation technique. Acta Neuropathol. 1999;98(5):481–7.PubMedCrossRef
10.
An SF, Groves M, Gray F, Scaravilli F. Early entry and widespread cellular involvement of HIV-1 DNA in brains of HIV-1 positive asymptomatic individuals. J Neuropathol Exp Neurol. 1999;58(11):1156–62.PubMedCrossRef
11.
Davis LE, Hjelle BL, Miller VE, et al. Early viral brain invasion in iatrogenic human immunodeficiency virus infection. Neurology. 1992;42(9):1736–9.PubMed
12.
Borjabad A, Brooks AI, Volsky DJ. Gene expression profiles of HIV-1-infected glia and brain: toward better understanding of the role of astrocytes in HIV-1-associated neurocognitive disorders. J Neuroimmune Pharmacol. 2010;5(1):44–62.PubMedCrossRef
13.
Ivey NS, MacLean AG, Lackner AA. Acquired immunodeficiency syndrome and the blood-brain barrier. J Neurovirol. 2009;15(2):111–22.PubMedCrossRef
14.
Dunfee R, Thomas ER, Gorry PR, Wang J, Ancuta P, Gabuzda D. Mechanisms of HIV-1 neurotropism. Curr HIV Res. 2006;4(3):267–78.PubMedCrossRef
15.
Adle-Biassette H, Levy Y, Colombel M, Poron F, Natchev S, Keohane C, Gray F. Neuronal apoptosis in HIV infection in adults. Neuropathol Appl Neurobiol. 1995;21(3):218–27.PubMedCrossRef
16.
Gray F, dle-Biassette H, Brion F, Ereau T, le MI, Levy V, Corcket G. Neuronal apoptosis in human immunodeficiency virus infection. J Neurovirol. 2000;6(Suppl 1):S38–43.PubMed
17.
Gray F, dle-Biassette H, Chretien F, de la Lorin GG, Force G, Keohane C. Neuropathology and neurodegeneration in human immunodeficiency virus infection. Pathogenesis of HIV-induced lesions of the brain, correlations with HIV-associated disorders and modifications according to treatments. Clin Neuropathol. 2001;20(4):146–55.PubMed
18.
Agrawal L, Louboutin JP, Reyes BA, Van Bockstaele EJ, Strayer DS. Antioxidant enzyme gene delivery to protect from HIV-1 gp120-induced neuronal apoptosis. Gene Ther. 2006;13(23):1645–56.PubMedCrossRef
19.
Louboutin JP, Reyes BA, Agrawal L, Maxwell CR, Van Bockstaele EJ, Strayer DS. Blood-brain barrier abnormalities caused by exposure to HIV-1 gp120–protection by gene delivery of antioxidant enzymes. Neurobiol Dis. 2010;38(2):313–25.PubMedCrossRef
20.
Louboutin JP, Reyes BA, Agrawal L, Van Bockstaele EJ, Strayer DS. HIV-1 gp120-induced neuroinflammation: relationship to neuron loss and protection by rSV40-delivered antioxidant enzymes. Exp Neurol. 2010;221(1):231–45.PubMedCrossRef
21.
Louboutin JP, Reyes BA, Agrawal L, Van BE, Strayer DS. Strategies for CNS-directed gene delivery: in vivo gene transfer to the brain using SV40-derived vectors. Gene Ther. 2007;14(12):939–49.PubMedCrossRef
22.
Chaudhuri A, Yang B, Gendelman HE, Persidsky Y, Kanmogne GD. STAT1 signaling modulates HIV-1-induced inflammatory responses and leukocyte transmigration across the blood-brain barrier. Blood. 2008;111(4):2062–72.PubMedCrossRef
23.
Kanmogne GD, Schall K, Leibhart J, Knipe B, Gendelman HE, Persidsky Y. HIV-1 gp120 compromises blood-brain barrier integrity and enhances monocyte migration across blood-brain barrier: implication for viral neuropathogenesis. J Cereb Blood Flow Metab. 2007;27(1):123–34.PubMedCrossRef
24.
Mukhtar M, Pomerantz RJ. Development of an in vitro blood-brain barrier model to study molecular neuropathogenesis and neurovirologic disorders induced by human immunodeficiency virus type 1 infection. J Hum Virol. 2000;3(6):324–34.PubMed
25.
Persidsky Y, Zheng J, Miller D, Gendelman HE. Mononuclear phagocytes mediate blood-brain barrier compromise and neuronal injury during HIV-1-associated dementia. J Leukoc Biol. 2000;68(3):413–22.PubMed
26.
Harrington PR, Schnell G, Letendre SL, et al. Cross-sectional characterization of HIV-1 env compartmentalization in cerebrospinal fluid over the full disease course. AIDS. 2009;23(8):907–15.PubMedCrossRef
27.
Pillai SK, Pond SL, Liu Y, et al. Genetic attributes of cerebrospinal fluid-derived HIV-1 env. Brain. 2006;129(Pt 7):1872–83.PubMedCrossRef
28.
Strain MC, Letendre S, Pillai SK, et al. Genetic composition of human immunodeficiency virus type 1 in cerebrospinal fluid and blood without treatment and during failing antiretroviral therapy. J Virol. 2005;79(3):1772–88.PubMedCrossRef
29.
Ritola K, Pilcher CD, Fiscus SA, et al. Multiple V1/V2 env variants are frequently present during primary infection with human immunodeficiency virus type 1. J Virol. 2004;78(20):11208–18.PubMedCrossRef
30.
Ritola K, Robertson K, Fiscus SA, Hall C, Swanstrom R. Increased human immunodeficiency virus type 1 (HIV-1) env compartmentalization in the presence of HIV-1-associated dementia. J Virol. 2005;79(16):10830–4.PubMedCrossRef
31.
Robertson K, Fiscus S, Kapoor C, et al. CSF, plasma viral load and HIV associated dementia. J Neurovirol. 1998;4(1):90–4.PubMedCrossRef
32.
Brew BJ, Pemberton L, Cunningham P, Law MG. Levels of human immunodeficiency virus type 1 RNA in cerebrospinal fluid correlate with AIDS dementia stage. J Infect Dis. 1997;175(4):963–6.PubMedCrossRef
33.
Scourfield A, Waters L, Nelson M. Spectrum of neurological disease in patients with discordant HIV-1 RNA levels in plasma and cerebrospinal fluid. J Infect. 2010;60(3):251–2.PubMedCrossRef
34.
Christo PP, Greco DB, Aleixo AW, Livramento JA. Factors influencing cerebrospinal fluid, plasma HIV-1 RNA detection rate in patients with, without opportunistic neurological disease during the HAART era. BMC Infect Dis. 2007;7:147.PubMedCrossRef
35.
Christo PP, Vilela MC, Bretas TL, Domingues RB, Greco DB, Livramento JA, Teixeira AL. Cerebrospinal fluid levels of chemokines in HIV infected patients with and without opportunistic infection of the central nervous system. J Neurol Sci. 2009;287(1–2):79–83.PubMedCrossRef
36.
Schnell G, Spudich S, Harrington P, Price RW, Swanstrom R. Compartmentalized human immunodeficiency virus type 1 originates from long-lived cells in some subjects with HIV-1-associated dementia. PLoS Pathog. 2009;5(4):e1000395.PubMedCrossRef
37.
Staprans S, Marlowe N, Glidden D, et al. Time course of cerebrospinal fluid responses to antiretroviral therapy: evidence for variable compartmentalization of infection. AIDS. 1999;13(9):1051–61.PubMedCrossRef
38.
Caragounis EC, Gisslen M, Lindh M, Nordborg C, Westergren S, Hagberg L, Svennerholm B. Comparison of HIV-1 pol and env sequences of blood, CSF, brain and spleen isolates collected ante-mortem and post-mortem. Acta Neurol Scand. 2008;117(2):108–16.PubMed
39.
Ohagen A, Devitt A, Kunstman KJ, et al. Genetic and functional analysis of full-length human immunodeficiency virus type 1 env genes derived from brain and blood of patients with AIDS. J Virol. 2003;77(22):12336–45.PubMedCrossRef
40.
Schnell G, Price RW, Swanstrom R, Spudich S. Compartmentalization and clonal amplification of HIV-1 variants in the cerebrospinal fluid during primary infection. J Virol. 2010;84(5):2395–407.PubMedCrossRef
41.
Chang J, Jozwiak R, Wang B, et al. Unique HIV type 1 V3 region sequences derived from six different regions of brain: region-specific evolution within host-determined quasispecies. AIDS Res Hum Retrovir. 1998;14(1):25–30.PubMedCrossRef
42.
Di SM, Gray F, Leitner T, Chiodi F. Analysis of ENV V3 sequences from HIV-1-infected brain indicates restrained virus expression throughout the disease. J Med Virol. 1996;49(1):41–8.CrossRef
43.
Di SM, Wilt S, Gray F, Dubois-Dalcq M, Chiodi F. HIV type 1 V3 sequences and the development of dementia during AIDS. AIDS Res Hum Retrovir. 1996;12(6):471–6.CrossRef
44.
Di SM, Sabri F, Leitner T, Svennerholm B, Hagberg L, Norkrans G, Chiodi F. Reverse transcriptase sequence of paired isolates of cerebrospinal fluid and blood from patients infected with human immunodeficiency virus type 1 during zidovudine treatment. J Clin Microbiol. 1995;33(2):352–5.
45.
Monno L, Di SM, Zimatore GB, et al. Measurement of viral sequences in cerebrospinal fluid of AIDS patients with cerebral white-matter lesions using polymerase chain reaction. AIDS. 1998;12(6):581–90.PubMedCrossRef
46.
Donaldson YK, Bell JE, Holmes EC, Hughes ES, Brown HK, Simmonds P. In vivo distribution and cytopathology of variants of human immunodeficiency virus type 1 showing restricted sequence variability in the V3 loop. J Virol. 1994;68(9):5991–6005.PubMed
47.
Gartner S, McDonald RA, Hunter EA, Bouwman F, Liu Y, Popovic M. Gp120 sequence variation in brain and in T-lymphocyte human immunodeficiency virus type 1 primary isolates. J Hum Virol. 1997;1(1):3–18.PubMed
48.
Hughes ES, Bell JE, Simmonds P. Investigation of the dynamics of the spread of human immunodeficiency virus to brain and other tissues by evolutionary analysis of sequences from the p17gag and env genes. J Virol. 1997;71(2):1272–80.PubMed
49.
Korber BT, Kunstman KJ, Patterson BK, Furtado M, McEvilly MM, Levy R, Wolinsky SM. Genetic differences between blood- and brain-derived viral sequences from human immunodeficiency virus type 1-infected patients: evidence of conserved elements in the V3 region of the envelope protein of brain-derived sequences. J Virol. 1994;68(11):7467–81.PubMed
50.
Morris A, Marsden M, Halcrow K, Hughes ES, Brettle RP, Bell JE, Simmonds P. Mosaic structure of the human immunodeficiency virus type 1 genome infecting lymphoid cells and the brain: evidence for frequent in vivo recombination events in the evolution of regional populations. J Virol. 1999;73(10):8720–31.PubMed
51.
Pang S, Vinters HV, Akashi T, O’Brien WA, Chen IS. HIV-1 env sequence variation in brain tissue of patients with AIDS-related neurologic disease. J Acquir Immune Defic Syndr. 1991;4(11):1082–92.PubMed
52.
Power C, McArthur JC, Johnson RT, Griffin DE, Glass JD, Perryman S, Chesebro B. Demented and nondemented patients with AIDS differ in brain-derived human immunodeficiency virus type 1 envelope sequences. J Virol. 1994;68(7):4643–9.PubMed
53.
van’t Wout AB, Ran LJ, Kuiken CL, Kootstra NA, Pals ST, Schuitemaker H. Analysis of the temporal relationship between human immunodeficiency virus type 1 quasispecies in sequential blood samples and various organs obtained at autopsy. J Virol. 1998;72(1):488–96.PubMed
54.
Wang TH, Donaldson YK, Brettle RP, Bell JE, Simmonds P. Identification of shared populations of human immunodeficiency virus type 1 infecting microglia and tissue macrophages outside the central nervous system. J Virol. 2001;75(23):11686–99.PubMedCrossRef
55.
Wong JK, Ignacio CC, Torriani F, Havlir D, Fitch NJ, Richman DD. In vivo compartmentalization of human immunodeficiency virus: evidence from the examination of pol sequences from autopsy tissues. J Virol. 1997;71(3):2059–71.PubMed
56.
Sheehy N, Desselberger U, Whitwell H, Ball JK. Concurrent evolution of regions of the envelope and polymerase genes of human immunodeficiency virus type 1 during zidovudine (AZT) therapy. J Gen Virol. 1996;77(Pt 5):1071–81.PubMedCrossRef
57.
Shapshak P, Segal DM, Crandall KA, et al. Independent evolution of HIV type 1 in different brain regions. AIDS Res Hum Retrovir. 1999;15(9):811–20.PubMedCrossRef
58.
Smit TK, Brew BJ, Tourtellotte W, Morgello S, Gelman BB, Saksena NK. Independent evolution of human immunodeficiency virus (HIV) drug resistance mutations in diverse areas of the brain in HIV-infected patients, with and without dementia, on antiretroviral treatment. J Virol. 2004;78(18):10133–48.PubMedCrossRef
59.
Smit TK, Wang B, Ng T, Osborne R, Brew B, Saksena NK. Varied tropism of HIV-1 isolates derived from different regions of adult brain cortex discriminate between patients with and without AIDS dementia complex (ADC): evidence for neurotropic HIV variants. Virology. 2001;279(2):509–26.PubMedCrossRef
60.
Gorry PR, Bristol G, Zack JA, et al. Macrophage tropism of human immunodeficiency virus type 1 isolates from brain and lymphoid tissues predicts neurotropism independent of coreceptor specificity. J Virol. 2001;75(21):10073–89.PubMedCrossRef
61.
Olivieri KC, Agopian KA, Mukerji J, Gabuzda D. Evidence for adaptive evolution at the divergence between lymphoid and brain HIV-1 nef genes. AIDS Res Hum Retrovir. 2010;26(4):495–500.PubMedCrossRef
62.
Thomas ER, Dunfee RL, Stanton J, Bogdan D, Kunstman K, Wolinsky SM, Gabuzda D. High frequency of defective vpu compared with tat and rev genes in brain from patients with HIV type 1-associated dementia. AIDS Res Hum Retrovir. 2007;23(4):575–80.PubMedCrossRef
63.
Thomas ER, Dunfee RL, Stanton J, et al. Macrophage entry mediated by HIV Envs from brain and lymphoid tissues is determined by the capacity to use low CD4 levels and overall efficiency of fusion. Virology. 2007;360(1):105–19.PubMedCrossRef
64.
Dunfee RL, Thomas ER, Wang J, Kunstman K, Wolinsky SM, Gabuzda D. Loss of the N-linked glycosylation site at position 386 in the HIV envelope V4 region enhances macrophage tropism and is associated with dementia. Virology. 2007;367(1):222–34.PubMedCrossRef
65.
Kuiken CL, Goudsmit J, Weiller GF, Armstrong JS, Hartman S, Portegies P, Dekker J, Cornelissen M. Differences in human immunodeficiency virus type 1 V3 sequences from patients with and without AIDS dementia complex. J Gen Virol. 1995;76(Pt 1):175–80.PubMedCrossRef
66.
Reddy RT, Achim CL, Sirko DA, Tehranchi S, Kraus FG, Wong-Staal F, Wiley CA. Sequence analysis of the V3 loop in brain and spleen of patients with HIV encephalitis. AIDS Res Hum Retrovir. 1996;12(6):477–82.PubMedCrossRef
67.
Zink MC, Brice AK, Kelly KM, et al. Simian immunodeficiency virus-infected macaques treated with highly active antiretroviral therapy have reduced central nervous system viral replication and inflammation but persistence of viral DNA. J Infect Dis. 2010;202(1):161–70. 20497048.PubMedCrossRef
68.
Zink MC, Laast VA, Helke KL, Brice AK, Barber SA, Clements JE, Mankowski JL. From mice to macaques–animal models of HIV nervous system disease. Curr HIV Res. 2006;4(3):293–305.PubMedCrossRef
69.
Zink MC, Clements JE. A novel simian immunodeficiency virus model that provides insight into mechanisms of human immunodeficiency virus central nervous system disease. J Neurovirol. 2002;8(Suppl 2):42–8.PubMedCrossRef
70.
Zink MC, Suryanarayana K, Mankowski JL, et al. High viral load in the cerebrospinal fluid and brain correlates with severity of simian immunodeficiency virus encephalitis. J Virol. 1999;73(12):10480–8.PubMed
71.
Reeve AB, Pearce NC, Patel K, Augustus KV, Novembre FJ. Neuropathogenic SIVsmmFGb genetic diversity and selection-induced tissue-specific compartmentalization during chronic infection and temporal evolution of viral genes in lymphoid tissues and regions of the central nervous system. AIDS Res Hum Retrovir. 2010;26(6):663–79.PubMedCrossRef
72.
Witwer KW, Gama L, Li M, et al. Coordinated regulation of SIV replication and immune responses in the CNS. PLoS One. 2009;4(12):e8129.PubMedCrossRef
73.
Clements JE, Li M, Gama L, Bullock B, Carruth LM, Mankowski JL, Zink MC. The central nervous system is a viral reservoir in simian immunodeficiency virus–infected macaques on combined antiretroviral therapy: a model for human immunodeficiency virus patients on highly active antiretroviral therapy. J Neurovirol. 2005;11(2):180–9.PubMed
74.
Clements JE, Babas T, Mankowski JL, Suryanarayana K, Piatak M Jr, Tarwater PM, Lifson JD, Zink MC. The central nervous system as a reservoir for simian immunodeficiency virus (SIV): steady-state levels of SIV DNA in brain from acute through asymptomatic infection. J Infect Dis. 2002;186(7):905–13.PubMedCrossRef
75.
Witwer KW, Sisk JM, Gama L, Clements JE. MicroRNA regulation of IFN-beta protein expression: rapid and sensitive modulation of the innate immune response. J Immunol. 2010;184(5):2369–76.PubMedCrossRef
76.
O’Brien WA. HIV-1 entry and reverse transcription in macrophages. J Leukoc Biol. 1994;56(3):273–7.PubMed
77.
O’Brien WA, Mao SH, Cao Y, Moore JP. Macrophage-tropic and T-cell line-adapted chimeric strains of human immunodeficiency virus type 1 differ in their susceptibilities to neutralization by soluble CD4 at different temperatures. J Virol. 1994;68(8):5264–9.PubMed
78.
Barber SA, Herbst DS, Bullock BT, Gama L, Clements JE. Innate immune responses and control of acute simian immunodeficiency virus replication in the central nervous system. J Neurovirol. 2004;10(Suppl 1):15–20.PubMed
79.
Barber SA, Gama L, Dudaronek JM, Voelker T, Tarwater PM, Clements JE. Mechanism for the establishment of transcriptional HIV latency in the brain in a simian immunodeficiency virus-macaque model. J Infect Dis. 2006;193(7):963–70.PubMedCrossRef
80.
Dudaronek JM, Barber SA, Clements JE. CUGBP1 is required for IFNbeta-mediated induction of dominant-negative CEBPbeta and suppression of SIV replication in macrophages. J Immunol. 2007;179(11):7262–9.PubMed
81.
Barber SA, Gama L, Li M, et al. Longitudinal analysis of simian immunodeficiency virus (SIV) replication in the lungs: compartmentalized regulation of SIV. J Infect Dis. 2006;194(7):931–8.PubMedCrossRef
82.
Sodora DL, Allan JS, Apetrei C, et al. Toward an AIDS vaccine: lessons from natural simian immunodeficiency virus infections of African nonhuman primate hosts. Nat Med. 2009;15(8):861–5. 19661993.PubMedCrossRef
83.
Broussard SR, Staprans SI, White R, Whitehead EM, Feinberg MB, Allan JS. Simian immunodeficiency virus replicates to high levels in naturally infected African green monkeys without inducing immunologic or neurologic disease. J Virol. 2001;75(5):2262–75.PubMedCrossRef
84.
Taaffe J, Chahroudi A, Engram J, et al. A five-year longitudinal analysis of sooty mangabeys naturally infected with simian immunodeficiency virus reveals a slow but progressive decline in CD4 + T-cell count whose magnitude is not predicted by viral load or immune activation. J Virol. 2010;84(11):5476–84.PubMedCrossRef
85.
Paiardini M, Pandrea I, Apetrei C, Silvestri G. Lessons learned from the natural hosts of HIV-related viruses. Ann Rev Med. 2009;60:485–95.PubMedCrossRef
86.
Pandrea I, Silvestri G, Apetrei C. AIDS in African nonhuman primate hosts of SIVs: a new paradigm of SIV infection. Curr HIV Res. 2009;7(1):57–72.PubMedCrossRef
87.
88.
89.
Jacquelin B, Mayau V, Targat B, et al. Nonpathogenic SIV infection of African green monkeys induces a strong but rapidly controlled type I IFN response. J Clin Invest. 2009;119(12):3544–55.PubMed
90.
Cumont MC, Diop O, Vaslin B, et al. Early divergence in lymphoid tissue apoptosis between pathogenic and nonpathogenic simian immunodeficiency virus infections of nonhuman primates. J Virol. 2008;82(3):1175–84.PubMedCrossRef
91.
Ziv Y, Ron N, Butovsky O, et al. Immune cells contribute to the maintenance of neurogenesis and spatial learning abilities in adulthood. Nat Neurosci. 2006;9(2):268–75. 16415867.PubMedCrossRef
92.
Lewitus GM, Cohen H, Schwartz M. Reducing post-traumatic anxiety by immunization. Brain Behav Immun. 2008;22(7):1108–14. 18562161.PubMedCrossRef
93.
Kipnis J, Cohen H, Cardon M, Ziv Y, Schwartz M. T cell deficiency leads to cognitive dysfunction: implications for therapeutic vaccination for schizophrenia and other psychiatric conditions. Proc Natl Acad Sci USA. 2004;101(21):8180–5. 15141078.PubMedCrossRef
94.
Lewitus GM, Wilf-Yarkoni A, Ziv Y, Shabat-Simon M, Gersner R, Zangen A, Schwartz M. Vaccination as a novel approach for treating depressive behavior. Biol Psychiatry. 2009;65(4):283–8. 18722594.PubMedCrossRef
95.
Moalem G, Leibowitz-Amit R, Yoles E, Mor F, Cohen IR, Schwartz M. Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy. Nat Med. 1999;5(1):49–55. 9883839.PubMedCrossRef
96.
Rapalino O, Lazarov-Spiegler O, Agranov E, et al. Implantation of stimulated homologous macrophages results in partial recovery of paraplegic rats. Nat Med. 1998;4(7):814–21. 9662373.PubMedCrossRef
97.
Hauben E, Agranov E, Gothilf A, Nevo U, Cohen A, Smirnov I, Steinman L, Schwartz M. Posttraumatic therapeutic vaccination with modified myelin self-antigen prevents complete paralysis while avoiding autoimmune disease. J Clin Invest. 2001;108(4):591–9. 11518733.PubMed
98.
Thompson PM, Dutton RA, Hayashi KM, Toga AW, Lopez OL, Aizenstein HJ, Becker JT. Thinning of the cerebral cortex visualized in HIV/AIDS reflects CD4 + T lymphocyte decline. Proc Natl Acad Sci USA. 2005;102(43):15647–52. 16227428.PubMedCrossRef
99.
Anthony IC, Ramage SN, Carnie FW, Simmonds P, Bell JE. Influence of HAART on HIV-related CNS disease and neuroinflammation. J Neuropathol Exp Neurol. 2005;64(6):529–36. 15977645.PubMed
100.
Eden A, Price RW, Spudich S, Fuchs D, Hagberg L, Gisslen M. Immune activation of the central nervous system is still present after >4 years of effective highly active antiretroviral therapy. J Infect Dis. 2007;196(12):1779–83. 18190258.PubMedCrossRef
101.
Ellis R, Langford D, Masliah E. HIV and antiretroviral therapy in the brain: neuronal injury and repair. Nat Rev Neurosci. 2007;8(1):33–44. 17180161.PubMedCrossRef
102.
Sacktor N, Lyles RH, Skolasky R, et al. HIV-associated neurologic disease incidence changes: Multicenter AIDS Cohort Study, 1990–1998. Neurology. 2001;56(2):257–60. 11160967.PubMed
103.
Sacktor N, Tarwater PM, Skolasky RL, McArthur JC, Selnes OA, Becker J, Cohen B, Miller EN. CSF antiretroviral drug penetrance and the treatment of HIV-associated psychomotor slowing. Neurology. 2001;57(3):542–4. 11502933.PubMed
104.
Marra CM, Lockhart D, Zunt JR, Perrin M, Coombs RW, Collier AC. Changes in CSF and plasma HIV-1 RNA and cognition after starting potent antiretroviral therapy. Neurology. 2003;60(8):1388–90. 12707454.PubMed
105.
Cysique LA, Maruff P, Brew BJ. Antiretroviral therapy in HIV infection: are neurologically active drugs important? Arch Neurol. 2004;61(11):1699–704. 15534181.PubMedCrossRef
106.
Shelburne SA 3rd, Hamill RJ, Rodriguez-Barradas MC, et al. Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Medicine (Baltimore). 2002;81(3):213–27. 11997718.CrossRef
107.
McCombe JA, Auer RN, Maingat FG, Houston S, Gill MJ, Power C. Neurologic immune reconstitution inflammatory syndrome in HIV/AIDS: outcome and epidemiology. Neurology. 2009;72(9):835–41. 19255411.PubMedCrossRef
108.
Kaul M, Garden GA, Lipton SA. Pathways to neuronal injury and apoptosis in HIV-associated dementia. Nature. 2001;410(6831):988–94. 11309629.PubMedCrossRef
109.
Power C, Gill MJ, Johnson RT. Progress in clinical neurosciences: the neuropathogenesis of HIV infection: host-virus interaction and the impact of therapy. Can J Neurol Sci. 2002;29(1):19–32. 11858531.PubMed
110.
The neurology of AIDS, Second edn. London: Oxford University Press; 2005.
111.
Ellis RJ, Deutsch R, Heaton RK, et al. Neurocognitive impairment is an independent risk factor for death in HIV infection. San Diego HIV Neurobehavioral Research Center Group. Arch Neurol. 1997;54(4):416–24. 9109743.PubMed
112.
Budka H. Neuropathology of human immunodeficiency virus infection. Brain Pathol. 1991;1(3):163–75. 1669705.PubMedCrossRef
113.
Spencer DC, Price RW. Human immunodeficiency virus and the central nervous system. Annu Rev Microbiol. 1992;46:655–93. 1444270.PubMedCrossRef
114.
McArthur JC, Hoover DR, Bacellar H, et al. Dementia in AIDS patients: incidence and risk factors Multicenter AIDS Cohort Study. Neurology. 1993;43(11):2245–52. 8232937.PubMed
115.
Gendelman HE, Lipton SA, Tardieu M, Bukrinsky MI, Nottet HS. The neuropathogenesis of HIV-1 infection. J Leukoc Biol. 1994;56(3):389–98. 8083614.PubMed
116.
Lipton SA, Gendelman HE. Seminars in medicine of the Beth Israel Hospital, Boston. Dementia associated with the acquired immunodeficiency syndrome. N Engl J Med. 1995;332(14):934–40. 7877652.PubMedCrossRef
117.
Bell JE. The neuropathology of adult HIV infection. Rev Neurol (Paris). 1998;154(12):816–29. 9932303.
118.
Nath A. Pathobiology of human immunodeficiency virus dementia. Semin Neurol. 1999;19(2):113–27. 10718533.PubMedCrossRef
119.
McArthur JC, Haughey N, Gartner S, Conant K, Pardo C, Nath A, Sacktor N. Human immunodeficiency virus-associated dementia: an evolving disease. J Neurovirol. 2003;9(2):205–21. 12707851.PubMed
120.
Cunningham PH, Smith DG, Satchell C, Cooper DA, Brew B. Evidence for independent development of resistance to HIV-1 reverse transcriptase inhibitors in the cerebrospinal fluid. AIDS. 2000;14(13):1949–54. 10997399.PubMedCrossRef
121.
Welch K, Morse A. The clinical profile of end-stage AIDS in the era of highly active antiretroviral therapy. AIDS Patient Care STDS. 2002;16(2):75–81. 11874639.PubMedCrossRef
122.
123.
Kramer-Hammerle S, Rothenaigner I, Wolff H, Bell JE, Brack-Werner R. Cells of the central nervous system as targets and reservoirs of the human immunodeficiency virus. Virus Res. 2005;111(2):194–213. 15885841.PubMedCrossRef
124.
Jones G, Power C. Regulation of neural cell survival by HIV-1 infection. Neurobiol Dis. 2006;21(1):1–17. 16298136.PubMedCrossRef
125.
Bansal AK, Mactutus CF, Nath A, Maragos W, Hauser KF, Booze RM. Neurotoxicity of HIV-1 proteins gp120 and Tat in the rat striatum. Brain Res. 2000;879(1–2):42–9. 11011004.PubMedCrossRef
126.
Agrawal L, Louboutin JP, Strayer DS. Preventing HIV-1 Tat-induced neuronal apoptosis using antioxidant enzymes: mechanistic and therapeutic implications. Virology. 2007;363(2):462–72. 17336361.PubMedCrossRef
127.
Corasaniti MT, Strongoli MC, Piccirilli S, et al. Apoptosis induced by gp120 in the neocortex of rat involves enhanced expression of cyclooxygenase type 2 and is prevented by NMDA receptor antagonists and by the 21-aminosteroid U-74389G. Biochem Biophys Res Commun. 2000;274(3):664–9.PubMedCrossRef
128.
Kaul M, Lipton SA. Chemokines and activated macrophages in HIV gp120-induced neuronal apoptosis. Proc Natl Acad Sci USA. 1999;96(14):8212–6.PubMedCrossRef
129.
Meucci O, Fatatis A, Simen AA, Bushell TJ, Gray PW, Miller RJ. Chemokines regulate hippocampal neuronal signaling and gp120 neurotoxicity. Proc Natl Acad Sci USA. 1998;95(24):14500–5.PubMedCrossRef
130.
Shi B, De GU, He J, Wang S, Lorenzo A, Busciglio J, Gabuzda D. Apoptosis induced by HIV-1 infection of the central nervous system. J Clin Invest. 1996;98(9):1979–90.PubMedCrossRef
131.
Hu S, Sheng WS, Lokensgard JR, Peterson PK, Rock RB. Preferential sensitivity of human dopaminergic neurons to gp120-induced oxidative damage. J Neurovirol. 2009;15(5–6):401–10.PubMedCrossRef
132.
Itoh K, Mehraein P, Weis S. Neuronal damage of the substantia nigra in HIV-1 infected brains. Acta Neuropathol. 2000;99(4):376–84.PubMedCrossRef
133.
Brenneman DE, Westbrook GL, Fitzgerald SP, Ennist DL, Elkins KL, Ruff MR, Pert CB. Neuronal cell killing by the envelope protein of HIV and its prevention by vasoactive intestinal peptide. Nature. 1988;335(6191):639–42. 2845276.PubMedCrossRef
134.
Dong J, Xiong H. Human immunodeficiency virus type 1 gp120 inhibits long-term potentiation via chemokine receptor CXCR4 in rat hippocampal slices. J Neurosci Res. 2006;83(3):489–96. 16400660.PubMedCrossRef
135.
136.
Trillo-Pazos G, McFarlane-Abdulla E, Campbell IC, Pilkington GJ, Everall IP. Recombinant nef HIV-IIIB protein is toxic to human neurons in culture. Brain Res. 2000;864(2):315–26. 10802040.PubMedCrossRef
137.
van Marle G, Henry S, Todoruk T, et al. Human immunodeficiency virus type 1 Nef protein mediates neural cell death: a neurotoxic role for IP-10. Virology. 2004;329(2):302–18. 15518810.PubMed
138.
Sporer B, Koedel U, Paul R, Kohleisen B, Erfle V, Fontana A, Pfister HW. Human immunodeficiency virus type-1 Nef protein induces blood-brain barrier disruption in the rat: role of matrix metalloproteinase-9. J Neuroimmunol. 2000;102(2):125–30. 10636480.PubMedCrossRef
139.
Anthony IC, Ramage SN, Carnie FW, Simmonds P, Bell JE. Accelerated Tau deposition in the brains of individuals infected with human immunodeficiency virus-1 before and after the advent of highly active anti-retroviral therapy. Acta Neuropathol. 2006;111(6):529–38. 16718349.PubMedCrossRef
140.
Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol. 2006;59(3):512–9. 16372280.PubMedCrossRef
141.
Brew BJ, Pemberton L, Blennow K, Wallin A, Hagberg L. CSF amyloid beta42 and tau levels correlate with AIDS dementia complex. Neurology. 2005;65(9):1490–2. 16275845.PubMedCrossRef
142.
Clifford DB, Fagan AM, Holtzman DM, Morris JC, Teshome M, Shah AR, Kauwe JS. CSF biomarkers of Alzheimer disease in HIV-associated neurologic disease. Neurology. 2009;73(23):1982–7. 19907013.PubMedCrossRef
143.
Pulliam L. HIV regulation of amyloid beta production. J Neuroimmune Pharmacol. 2009;4(2):213–7. 19288202.PubMedCrossRef
144.
Xu J, Ikezu T. The comorbidity of HIV-associated neurocognitive disorders and Alzheimer’s disease: a foreseeable medical challenge in post-HAART era. J Neuroimmune Pharmacol. 2009;4(2):200–12. 19016329.PubMedCrossRef
145.
Behnisch T, Francesconi W, Sanna PP. HIV secreted protein Tat prevents long-term potentiation in the hippocampal CA1 region. Brain Res. 2004;1012(1–2):187–9. 15158177.PubMedCrossRef
146.
Xiong H, Zeng YC, Zheng J, Thylin M, Gendelman HE. Soluble HIV-1 infected macrophage secretory products mediate blockade of long-term potentiation: a mechanism for cognitive dysfunction in HIV-1-associated dementia. J Neurovirol. 1999;5(5):519–28. 10568889.PubMedCrossRef
147.
Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416(6880):535–9. 11932745.PubMedCrossRef
148.
Aksenov MY, Aksenova MV, Mactutus CF, Booze RM. HIV-1 protein-mediated amyloidogenesis in rat hippocampal cell cultures. Neurosci Lett. 2010;475(3):174–8. 20363291.PubMedCrossRef
149.
Harris-White ME, Chu T, Balverde Z, Sigel JJ, Flanders KC, Frautschy SA. Effects of transforming growth factor-beta (isoforms 1–3) on amyloid-beta deposition, inflammation, and cell targeting in organotypic hippocampal slice cultures. J Neurosci. 1998;18(24):10366–74. 9852574.PubMed
150.
Harris-White ME, Balverde Z, Lim GP, Kim P, Miller SA, Hammer H, Galasko D, Frautschy SA. Role of LRP in TGFbeta2-mediated neuronal uptake of Abeta and effects on memory. J Neurosci Res. 2004;77(2):217–28. 15211588.PubMedCrossRef
151.
Eslami P, Johnson MF, Terzakaryan E, Chew C, Harris-White ME. TGF beta2-induced changes in LRP-1/T beta R-V and the impact on lysosomal A beta uptake and neurotoxicity. Brain Res. 2008;1241:176–87. 18804458.PubMedCrossRef
152.
Hall JR, Short SC. Management of glioblastoma multiforme in HIV patients: a case series and review of published studies. Clin Oncol (R Coll Radiol). 2009;21(8):591–7. 19589665.
153.
Rosenblum ML, Levy RM, DE Bredesen, So YT, Wara W, Ziegler JL. Primary central nervous system lymphomas in patients with AIDS. Ann Neurol. 1988;23(Suppl):S13–6. 2894803.PubMedCrossRef
154.
Welch K, Finkbeiner W, Alpers CE, Blumenfeld W, Davis RL, Smuckler EA, Beckstead JH. Autopsy findings in the acquired immune deficiency syndrome. JAMA. 1984;252(9):1152–9. 6471338.PubMedCrossRef
155.
Sparano JA, Anand K, Desai J, Mitnick RJ, Kalkut GE, Hanau LH. Effect of highly active antiretroviral therapy on the incidence of HIV-associated malignancies at an urban medical center. J Acquir Immune Defic Syndr. 1999;21(Suppl 1):S18–22. 10430213.PubMed
156.
Inungu J, Melendez MF, Montgomery JP. AIDS-related primary brain lymphoma in Michigan, January 1990 to December 2000. AIDS Patient Care STDS. 2002;16(3):107–12. 11945206.PubMedCrossRef
157.
Tanner JE, Alfieri C. The Epstein-Barr virus and post-transplant lymphoproliferative disease: interplay of immunosuppression, EBV, and the immune system in disease pathogenesis. Transpl Infect Dis. 2001;3(2):60–9. 11395971.PubMedCrossRef
158.
Gasser O, Bihl FK, Wolbers M, et al. HIV patients developing primary CNS lymphoma lack EBV-specific CD4+T cell function irrespective of absolute CD4+T cell counts. PLoS Med. 2007;4(3):e96. 17388662.PubMedCrossRef
159.
Blumenthal DT, Raizer JJ, Rosenblum MK, Bilsky MH, Hariharan S, Abrey LE. Primary intracranial neoplasms in patients with HIV. Neurology. 1999;52(8):1648–51. 10331693.PubMed
160.
Moulignier A, Mikol J, Pialoux G, Eliaszewicz M, Thurel C, Thiebaut JB. Cerebral glial tumors and human immunodeficiency virus-1 infection. More than a coincidental association. Cancer. 1994;74(2):686–92. 8033048.PubMedCrossRef
161.
Tacconi L, Stapleton S, Signorelli F, Thomas DG. Acquired immune deficiency syndrome (AIDS) and cerebral astrocytoma. Clin Neurol Neurosurg. 1996;98(2):149–51. 8836588.PubMedCrossRef
162.
Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ, Smyth MJ, Schreiber RD. Adaptive immunity maintains occult cancer in an equilibrium state. Nature. 2007;450(7171):903–7. 18026089.PubMedCrossRef
163.
Salvati M, Frati A, Caroli E, Russo N, Polli FM, Domenicucci M, Delfini R. Glioblastoma in kidney transplant recipients. Report of five cases. J Neurooncol. 2003;63(1):33–7. 12814252.PubMedCrossRef
164.
Schiff D, O’Neill B, Wijdicks E, Antin JH, Wen PY. Gliomas arising in organ transplant recipients: an unrecognized complication of transplantation? Neurology. 2001;57(8):1486–8. 11673595.PubMed
165.
Hajjar M, Lacoste D, Brossard G, Morlat P, Dupon M, Salmi LR, Dabis F. Non-acquired immune deficiency syndrome-defining malignancies in a hospital-based cohort of human immunodeficiency virus-infected patients: Bordeaux, France, 1985–1991. Groupe d’Epidemiologie Clinique du SIDA en Aquitaine. J Natl Cancer Inst. 1992;84(20):1593–5. 1404453.PubMedCrossRef
166.
Geleziunas R, Schipper HM, Wainberg MA. Pathogenesis and therapy of HIV-1 infection of the central nervous system. AIDS. 1992;6(12):1411–26. 1337255.PubMedCrossRef
167.
Taylor JP, Cupp C, Diaz A, Chowdhury M, Khalili K, Jimenez SA, Amini S. Activation of expression of genes coding for extracellular matrix proteins in Tat-producing glioblastoma cells. Proc Natl Acad Sci USA. 1992;89(20):9617–21. 1409674.PubMedCrossRef
168.
Wahl SM, Allen JB, Hines KL, Imamichi T, Wahl AM, Furcht LT, McCarthy JB. Synthetic fibronectin peptides suppress arthritis in rats by interrupting leukocyte adhesion and recruitment. J Clin Invest. 1994;94(2):655–62. 8040319.PubMedCrossRef
169.
Selmaj KW, Farooq M, Norton WT, Raine CS, Brosnan CF. Proliferation of astrocytes in vitro in response to cytokines. A primary role for tumor necrosis factor. J Immunol. 1990;144(1):129–35. 2104886.PubMed
170.
Maxwell M, Galanopoulos T, Neville-Golden J, Antoniades HN. Effect of the expression of transforming growth factor-beta 2 in primary human glioblastomas on immunosuppression and loss of immune surveillance. J Neurosurg. 1992;76(5):799–804. 1373442.PubMedCrossRef
171.
Emdad L, Sarkar D, Su ZZ, Lee SG, Kang DC, Bruce JN, Volsky DJ, Fisher PB. Astrocyte elevated gene-1: recent insights into a novel gene involved in tumor progression, metastasis and neurodegeneration. Pharmacol Ther. 2007;114(2):155–70. 17397930.PubMedCrossRef
172.
Sarkar D, Emdad L, Lee SG, Yoo BK, Su ZZ, Fisher PB. Astrocyte elevated gene-1: far more than just a gene regulated in astrocytes. Cancer Res. 2009;69(22):8529–35. 19903854.PubMedCrossRef
173.
Kang DC, Su ZZ, Sarkar D, Emdad L, Volsky DJ, Fisher PB. Cloning and characterization of HIV-1-inducible astrocyte elevated gene-1, AEG-1. Gene. 2005;353(1):8–15. 15927426.PubMedCrossRef
174.
Lee SG, Jeon HY, Su ZZ, Richards JE, Vozhilla N, Sarkar D, Van Maerken T, Fisher PB. Astrocyte elevated gene-1 contributes to the pathogenesis of neuroblastoma. Oncogene. 2009;28(26):2476–84. 19448665.PubMedCrossRef
175.
Liu H, Song X, Liu C, Xie L, Wei L, Sun R. Knockdown of astrocyte elevated gene-1 inhibits proliferation and enhancing chemo-sensitivity to cisplatin or doxorubicin in neuroblastoma cells. J Exp Clin Cancer Res. 2009;28:19. 19216799.PubMedCrossRef
176.
Ranki A, Nyberg M, Ovod V, Haltia M, Elovaara I, Raininko R, Haapasalo H, Krohn K. Abundant expression of HIV Nef and Rev proteins in brain astrocytes in vivo is associated with dementia. AIDS. 1995;9(9):1001–8. 8527071.PubMedCrossRef
177.
Kramer-Hammerle S, Kohleisen B, Hohenadl C, Shumay E, Becker I, Erfle V, Schmidt J. HIV type 1 Nef promotes neoplastic transformation of immortalized neural cells. AIDS Res Hum Retrovir. 2001;17(7):597–602. 11375055.PubMedCrossRef
178.
Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994;331(18):1173–80.PubMedCrossRef
179.
Van Rie A, Mupuala A, Dow A. Impact of the HIV/AIDS epidemic on the neurodevelopment of preschool-aged children in Kinshasa, Democratic Republic of the Congo. Pediatrics. 2008;122(1):e123–8. 18595957.PubMedCrossRef
180.
Diamond GW, Kaufman J, Belman AL, Cohen L, Cohen HJ, Rubinstein A. Characterization of cognitive functioning in a subgroup of children with congenital HIV infection. Arch Clin Neuropsychol. 1987;2(3):245–56. 14589616.PubMed
181.
Epstein LG, Sharer LR, Oleske JM, Connor EM, Goudsmit J, Bagdon L, Robert-Guroff M, Koenigsberger MR. Neurologic manifestations of human immunodeficiency virus infection in children. Pediatrics. 1986;78(4):678–87. 2429248.PubMed
182.
Van RA, Harrington PR, Dow A, Robertson K. Neurologic and neurodevelopmental manifestations of pediatric HIV/AIDS: a global perspective. Eur J Paediatr Neurol. 2007;11(1):1–9.CrossRef
183.
Belman AL. Pediatric neuro-AIDS. Update. Neuroimaging Clin N Am. 1997;7(3):593–613.PubMed
184.
Chase C, Vibbert M, Pelton SI, Coulter DL, Cabral H. Early neurodevelopmental growth in children with vertically transmitted human immunodeficiency virus infection. Arch Pediatr Adolesc Med. 1995;149(8):850–5.PubMed
185.
Smith R, Malee K, Leighty R, Brouwers P, Mellins C, Hittelman J, Chase C, Blasini I. Effects of perinatal HIV infection and associated risk factors on cognitive development among young children. Pediatrics. 2006;117(3):851–62.PubMedCrossRef
186.
Chase C, Ware J, Hittelman J, et al. Early cognitive and motor development among infants born to women infected with human immunodeficiency virus. Women and Infants Transmission Study Group. Pediatrics. 2000;106(2):E25.PubMedCrossRef
187.
Thorne C, Newell ML. Safety of agents used to prevent mother-to-child transmission of HIV: is there any cause for concern? Drug Saf. 2007;30(3):203–13.PubMedCrossRef
188.
Bulterys M, Nesheim S, Abrams EJ, Palumbo P, Farley J, Lampe M, Fowler MG. Lack of evidence of mitochondrial dysfunction in the offspring of HIV-infected women. Retrospective review of perinatal exposure to antiretroviral drugs in the Perinatal AIDS Collaborative Transmission Study. Ann NY Acad Sci. 2000;918:212–21.PubMedCrossRef
189.
Williams PL, Marino M, Malee K, Brogly S, Hughes MD, Mofenson LM. Neurodevelopment and in utero antiretroviral exposure of HIV-exposed uninfected infants. Pediatrics. 2010;125(2):e250–60. 20083530.PubMedCrossRef
190.
Boksa P. Effects of prenatal infection on brain development and behavior: a review of findings from animal models; 2010; (1090–2139 (Electronic)).
191.
Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006;12(12):1365–71.PubMedCrossRef
192.
Ancuta P, Kamat A, Kunstman KJ, et al. Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients. PLoS One. 2008;3(6):e2516. 18575590.PubMedCrossRef
193.
Teeling JL, Perry VH. Systemic Infection and inflammation in acute CNS injury and chronic neurodegeneration: underlying mechanisms. Neuroscience. 2009;158:1062–73.PubMedCrossRef
194.
Ahrne S, Lonnermark E, Wold AE, et al. Lactobacilli in the intestinal microbiota of Swedish infants. Microbes Infect. 2005;7(11–12):1256–62.PubMedCrossRef
195.
Wold AE, Adlerberth I. Breast feeding and the intestinal microflora of the infant–implications for protection against infectious diseases. Adv Exp Med Biol. 2000;478:77–93.PubMedCrossRef
196.
Qing G, Howlett S, Bortolussi R. Lipopolysaccharide binding proteins on polymorphonuclear leukocytes: comparison of adult and neonatal cells. Infect Immun. 1996;64(11):4638–42.PubMed
197.
Wallet MA, Rodriguez CA, Yin L, Saporta S, Chinratanapisit S, Hou W, Sleasman JW, Goodenow MM. Microbial translocation induces persistent macrophage activation unrelated to HIV-1 levels or T-cell activation following therapy. AIDS. 2010;24(9):1281–90.PubMedCrossRef
198.
Ho DD, Rota TR, Schooley RT, et al. Isolation of HTLV-III from cerebrospinal fluid and neural tissues of patients with neurologic syndromes related to the acquired immunodeficiency syndrome. N Engl J Med. 1985;313(24):1493–7. 2999591.PubMedCrossRef
199.
Gonzalez-Scarano F, Martin-Garcia J. The neuropathogenesis of AIDS. Nat Rev Immunol. 2005;5(1):69–81. 15630430.PubMedCrossRef
200.
201.
Schwartz M, Shechter R. Protective autoimmunity functions by intracranial immunosurveillance to support the mind: the missing link between health and disease. Mol Psychiatry. 2010;15:342–54.PubMedCrossRef
Metadata
Title
Thinking about HIV: the intersection of virus, neuroinflammation and cognitive dysfunction
Authors
K. Grovit-Ferbas
M. E. Harris-White
Publication date
01-12-2010
Publisher
Humana Press Inc
Published in
Immunologic Research / Issue 1-3/2010
Print ISSN: 0257-277X
Electronic ISSN: 1559-0755
DOI
https://doi.org/10.1007/s12026-010-8166-x

Other articles of this Issue 1-3/2010

Immunologic Research 1-3/2010 Go to the issue

OriginalPaper

A new functional role of HIV-1 integrase during uncoating of the viral core

OriginalPaper

Translating insights from persistent LCMV infection into anti-HIV immunity

OriginalPaper

A challenge for the future: aging and HIV infection

OriginalPaper

Biology and pathophysiology of the new human retrovirus XMRV and its association with human disease

EditorialNotes

Introduction

OriginalPaper

HIV-associated immune dysfunction and viral infection: role in the pathogenesis of AIDS-related lymphoma